Captor Therapeutics SA (CTX) Stock Statistics & Valuation Metrics

Captor Therapeutics SA has a market cap or net worth of zł497.47M. The enterprise value is zł424.19M.

Captor Therapeutics SA has 6,353,397 shares outstanding. The number of shares has decreased by -2.65% in one year.

Captor Therapeutics SA’s return on equity (ROE) is -1.79 and return on invested capital (ROIC) is -195.82%.

The current PE Ratio of Captor Therapeutics SA is ―. Captor Therapeutics SA’s PEG ratio is 1.22.

In the last 12 months, Captor Therapeutics SA had revenue of 4.66M and earned -42.00M in profits. Earnings per share was -7.61.

In the last 12 months, operating cash flow was -36.34M and capital expenditures -210.00K, giving a free cash flow of -36.55M billion.

Captor Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―

Captor Therapeutics SA upcoming earnings date is Jun 2, 2026, TBA (Confirmed).

Captor Therapeutics SA as a current ratio of 2.27, with Debt / Equity ratio of 15.23%

In the past 12 months, Captor Therapeutics SA has paid 0.00 in taxes.

Captor Therapeutics SA EV to EBITDA ratio is -7.99, with an EV/FCF ratio of -10.68.

Captor Therapeutics SA has zł32.11M in cash and marketable securities with zł3.58M in debt, giving a net cash position of zł28.53M billion.

Gross margin is 51.20%, with operating margin of -1141.78%, and net profit margin of -901.22%.

The average price target for Captor Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―